GO
Loading...

Carlyle Group finalizes offer for JNJ unit

Scott Eelis | Bloomberg | Getty Images

Johnson & Johnson said on Thursday it will sell its ortho clinical diagnostics unit to private equity firm Carlyle Group for $4.15 billion, a year after announcing it was considering spinning off or selling the slow-growing business.

The companies said in separate statements that, if approved, the deal should close in the middle of 2014.

(Read more: 'Things are not cheap,' says dealmaker Rubenstein)

Reuters reported in December that Carlyle was nearing an agreement to buy Johnson & Johnson's ortho clinical diagnostics unit for about $4 billion. It beat the Blackstone Group, which had made a bid with conglomerate Danaher, sources said at that time.

"This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson,'' Johnson & Johnson Chief Executive Officer Alex Gorsky said in a statement.

In January 2013, J&J said it was considering the sale or spin-off of the unit, whose products include equipment for laboratory diagnostics and blood transfusion screening. The unit was ranked fifth among competitors based on sales. J&J's businesses typically rank first or second in their markets.

(Read more: Charter CEO presses 'rich and fair' TWC offer)

Shares of Johnson & Johnson were up 0.2 percent in premarket trading on the New York Stock Exchange.

—By Reuters

Contact M&A

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More*